The Drugs Controller General of India (DCGI) has formally announced the final approval for Oxford-AstraZeneca “Covishield” and Bharat Biotech “Covaxin” vaccines against the coronavirus disease (Covid-19) for emergency use. CDSCO (Central Drugs Standard Control Organisation) accepts the subject expert committee reform rations on Serum and Bharat Biotech Covid vaccines.
WARRIOR 4.0 | Banking Awareness Batch for SBI, RRB, RBI and IBPS Exams | Bilingual | Live Class
The subject expert committee (SEC) under CDSCO had recommended Oxford-AstraZeneca’s vaccine, which is being manufactured by the Serum Institute of India (SII) as Covishield, for emergency use and Covaxin for restricted use.
Covaxin is the indigenous vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Important takeaways for all competitive exams:
- Serum Institute of India CEO: Adar Poonawalla.
- Serum Institute of IndiaFounder: Cyrus S. Poonawalla.
- Serum Institute of IndiaFounded: 1966.
- Serum Institute of India Headquarters location: Pune.